Journal Article

Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience

Esmail, Abdullah, Ajewole, Veronica B., Abdelrahim, Maen, Umoru, Godsfavour, Abdelrahim, Waseem, Abboud, Karen, Al-Najjar, Ebtesam, Khasawneh, Bayan

2025

Overview

Background: Colorectal carcinoma (CRC) is one of the most common cancer types along with breast, prostate, and lung cancer. Many patients with CRC present with metastatic disease despite receiving standard first- and second-line therapies; thus emerges the demand for implementing new therapies that could improve outcomes among CRC patients. This case series was conducted to assess the efficacy and safety of regorafenib plus 5-fluorouracil (5-FU) in patients with refractory metastatic CRC (mCRC). Methods: We conducted a retrospective analysis of data from adult patients aged 18 and above who were diagnosed with refractory mCRC and received regorafenib plus 5-FU combination therapy at Houston Methodist Hospital between November 2017 and October 2023. Our study focuses on assessing key outcomes, including Overall Survival [OS], Progression-Free Survival [PFS], and safety. Results: Among the 12 patients we included in this study who underwent regorafenib plus 5-FU combination therapy for refractory mCRC after receiving at least three prior lines of treatment, the best response for six patients (50%) was successfully achieved, with disease control within 7–12 weeks from therapy initiation. Patients had an overall good tolerance for this treatment regimen and reported only the most common adverse events, including Hand-Foot Syndrome (HFS), mucositis, and hypertension (HTN), which were mostly resolved with dose adjustment of medications. Conclusions: This study highlights that using a combination of regorafenib plus 5-FU can be a potential treatment option for patients with refractory mCRC. Additional research, including prospective clinical trials, is required to assess the effectiveness and safety of regorafenib and 5-FU combination therapy in comparison to other currently limited treatment options.

• Publisher: MDPI AG,MDPI
• Subject: 5-Fluorouracil / Antimitotic agents / Antineoplastic agents / Breast cancer / Cancer / Cancer therapies / Care and treatment / Cell death / Chemotherapy / Clinical trials / Colorectal cancer / Combination therapy / Complications and side effects / Disease control / Dosage and administration / Drug dosages / Drug therapy / Drug therapy, Combination / Epidermal growth factor / Fluorouracil / Hypotheses / Kinases / Lung cancer / Metabolites / Metastases / Metastasis / Mucositis / multi-kinase inhibitor / Patient outcomes / Patients / Prostate cancer / refractory mCRC / regorafenib plus 5-FU / Survival / Vascular endothelial growth factor / Women